spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Colin Goddard 

 HSMN NewsFeed - 22 Apr 2020
FoRx Therapeutics AG Raises EUR 10 Million Seed Round and Becomes First Company to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 5 Dec 2016
Mission Therapeutics Appoints Colin Goddard as Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jul 2012
Coferon, Inc. Announces $12 Million Series B Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 14 Dec 2010
Human Genome Sciences Appoints Colin Goddard, Ph.D., to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Apr 2010
OSI Pharmaceuticals Announces That Tarceva(R) Received Approval in the European Union for Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Mar 2010
OSI Pharmaceuticals Confirms Receipt of Unsolicited Proposal From Astellas Pharma
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 1 Mar 2010
Astellas Pharma Inc. Offers to Acquire OSI Pharmaceuticals for $52.00 Per Share in Cash
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 3 Sep 2009
OSI Pharmaceuticals Initiates Phase III Registration-Oriented Study for OSI-906 in Adrenocortical Carcinoma and Phase I/II Study in Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Mar 2009
OSI Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Tarceva as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Sep 2007
OSI Pharmaceuticals Announces Patent Term Extension for Tarceva(R) (erlotinib)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Aug 2007
Ophthotech Raises $36 Million; In-Licenses Two Compounds for Macular Degeneration
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 27 Jul 2007
OSI Pharmaceuticals Announces Agreement to Divest Anti-Platelet Derived Growth Factor (PDGF) Program
Biopharmaceuticals Ophthalmology Acquisitions
 HSMN NewsFeed - 5 Jan 2007
OSI Pharmaceuticals Licenses Its Glucokinase Activator Program for the Treatment of Type 2 Diabetes to Eli Lilly and Company
Biopharmaceuticals Endocrinology Licensing
 HSMN NewsFeed - 5 Jan 2007
Lilly and OSI Pharmaceuticals Announce Licensing Agreement
Biopharmaceuticals Endocrinology Licensing
 HSMN NewsFeed - 18 Dec 2006
OSI Pharmaceuticals Announces Appointment of Pablo J. Cagnoni, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 32

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 32 additional stories matching:
Colin Goddard
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.